




Searching News Database: Sapacitabine
HSMN NewsFeed - 11 Sep 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors
HSMN NewsFeed - 1 Jul 2010
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
Cyclacel Pharmaceuticals Announces FDA Orphan Drug Designation for Sapacitabine in Both AML and MDS
HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
HSMN NewsFeed - 27 May 2008
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
Cyclacel's Sapacitabine Receives Orphan Designation for AML & MDS From EU Regulators
HSMN NewsFeed - 8 Oct 2007
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
Cyclacel Pharmaceuticals Acquires Specialty Pharmaceutical Business Focused on the Oncology Market
HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
HSMN NewsFeed - 13 Dec 2006
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
HSMN NewsFeed - 24 Oct 2006
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development
Cyclacel Pharmaceuticals Names John Womelsdorf, Ph.D., Vice President, Business Development